Faculty Bio

Dr. Mony received his Ph.D (Haematology) from The University of Nottingham, UK. He worked on targeting of minimal residual disease in Acute Myeloid Leukemia. He developed a ‘niche-like’ condition for testing the chemosensitivity of leukemic stem and progenitor cells. Dr. Mony had identified multiple signaling pathways involved in the survival of leukemic stem and progenitor cells. He received prestigious awards such as Overseas Research Scholarship and Developing Solutions Scholarship (University of Nottingham, UK). He was also a recipient of the British Association of Cancer Research student award during his Ph.D time. He had his postdoctoral training as a senior fellow in a collaborative research programme at Memorial Sloan-Kettering Cancer Centre, USA, and Broad Institute of MIT and Harvard, USA. His expertise and training includes hemato-oncology, tumor microenvironment, preclinical drug discovery (small molecules), pre-clinical mice model development of cancers, and induced pluripotent stem cells (iPSC). He is trained and certified in rodent major surgical procedures from Cornell University, USA, and Memorial Sloan-Kettering Cancer Center, USA. He got trained in iPSC generation and differentiation from The University of Queensland and Monash University, Australia.

Dr. Mony joined Amrita Center for Nanosciences and Molecular Medicine as Assistant Professor in April 2009. Dr. Mony’s Stem cell and translational lab is focused mainly in two areas. Firstly in finding out the molecular heterogeneity and identification of novel targets in AML cells treated with various therapeutic agents, and secondly, in the generation and differentiation of iPS cells for drug screening and disease modeling applications. He is also heading the advanced immunohematology and flowcytometry facility of the center for disease diagnosis and research. His publications are in major international journals of repute such as Leukemia, Blood, Haematologica, Molecular Oncology etc.

His research interest includes Leukemic Stem Cells/Acute Myeloid Leukemia and targeting, Tumor microenvironment, Immunotherapy, Pre-clinical mice model development, proteomics and iPSC.